BEAM vs. KYMR, NTLA, EDIT, REPL, SGMO, PCVX, EXEL, RVMD, HALO, and KRYS
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Kymera Therapeutics (KYMR), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Replimune Group (REPL), Sangamo Therapeutics (SGMO), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), and Krystal Biotech (KRYS). These companies are all part of the "medical" sector.
Kymera Therapeutics (NASDAQ:KYMR) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.
Kymera Therapeutics has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.
Beam Therapeutics received 1 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 51.25% of users gave Beam Therapeutics an outperform vote while only 48.19% of users gave Kymera Therapeutics an outperform vote.
99.7% of Beam Therapeutics shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by insiders. Comparatively, 4.2% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Beam Therapeutics has higher revenue and earnings than Kymera Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Beam Therapeutics has a net margin of -37.33% compared to Beam Therapeutics' net margin of -194.67%. Kymera Therapeutics' return on equity of -15.46% beat Beam Therapeutics' return on equity.
Kymera Therapeutics presently has a consensus target price of $42.70, suggesting a potential upside of 32.98%. Beam Therapeutics has a consensus target price of $40.18, suggesting a potential upside of 68.69%. Given Kymera Therapeutics' higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Kymera Therapeutics.
In the previous week, Beam Therapeutics had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 4 mentions for Beam Therapeutics and 3 mentions for Kymera Therapeutics. Beam Therapeutics' average media sentiment score of 0.47 beat Kymera Therapeutics' score of 0.29 indicating that Kymera Therapeutics is being referred to more favorably in the media.
Summary
Beam Therapeutics beats Kymera Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Beam Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
